Nurix Q3 update

 Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA

Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, follicular lymphoma and marginal zone lymphoma patients

Reinitiated enrollment for NX-2127 in a Phase 1a/b trial in oncology

Presented preclinical data on Degrader-Antibody Conjugates (DACs), a new class of therapeutics

Well capitalized with cash and marketable securities of $457.5 million

https://www.globenewswire.com/news-release/2024/10/11/2962186/0/en/Nurix-Therapeutics-Reports-Third-Quarter-Fiscal-2024-Financial-Results-and-Provides-a-Corporate-Update.html